Literature DB >> 26334743

Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis.

Reuben Kiggundu1, Bozena M Morawski, Nathan C Bahr, Joshua Rhein, Abdu K Musubire, Darlisha A Williams, Mahsa Abassi, Henry W Nabeta, Kathy H Hullsiek, David B Meya, David R Boulware.   

Abstract

The effect of tenofovir and amphotericin coadministration on kidney function is poorly characterized. We measured creatinine during induction therapy and at 4 weeks after diagnosis in Ugandans undergoing cryptococcal meningitis therapy and classified as not receiving antiretroviral therapy (ART), receiving nontenofovir ART or receiving tenofovir-based ART. Longitudinal creatinine changes and grade 2-4 creatinine adverse events were evaluated across groups. Creatinine concentrations were similar across ART groups. At 4 weeks after diagnosis, creatinine was 0.25 mg/dL higher than at diagnosis, but similar across groups. Adverse event incidence was also similar across ART groups. Tenofovir and amphotericin coadministration did not increase the risk of kidney dysfunction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26334743      PMCID: PMC4713303          DOI: 10.1097/QAI.0000000000000812

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

Review 1.  Amphotericin B nephrotoxicity.

Authors:  Gilbert Deray
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

2.  Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.

Authors:  František Trejtnar; Jana Mandíková; Jana Kočíncová; Marie Volková
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  Risk factors for amphotericin B-induced nephrotoxicity.

Authors:  A D Luber; L Maa; M Lam; B J Guglielmo
Journal:  J Antimicrob Chemother       Date:  1999-02       Impact factor: 5.790

4.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

5.  Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Joel E Gallant; Khalil G Ghanem; Patricia Emmanuel; Barry S Zingman; Michael A Horberg
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

6.  Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration.

Authors:  Takahisa Yano; Yoshinori Itoh; Eiko Kawamura; Asuka Maeda; Nobuaki Egashira; Motohiro Nishida; Hitoshi Kurose; Ryozo Oishi
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

7.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

8.  Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.

Authors:  Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2013-12-06       Impact factor: 9.079

9.  Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Authors:  Sophie Jose; Lisa Hamzah; Lucy J Campbell; Teresa Hill; Martin Fisher; Clifford Leen; Richard Gilson; John Walsh; Mark Nelson; Phillip Hay; Margaret Johnson; David Chadwick; Dorothea Nitsch; Rachael Jones; Caroline A Sabin; Frank A Post
Journal:  J Infect Dis       Date:  2014-02-28       Impact factor: 5.226

10.  Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate.

Authors:  Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey
Journal:  JAMA       Date:  2012-05-09       Impact factor: 56.272

View more
  2 in total

Review 1.  Integrated therapy for HIV and cryptococcosis.

Authors:  Sirawat Srichatrapimuk; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2016-11-29       Impact factor: 2.250

2.  A Highly Active Triterpene Derivative Capable |of Biofilm Damage to Control Cryptococcus spp.

Authors:  Maria E Krummenauer; William Lopes; Ane W A Garcia; Augusto Schrank; Simone C B Gnoatto; Daniel F Kawano; Marilene H Vainstein
Journal:  Biomolecules       Date:  2019-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.